Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling
Paeonol (PAE) is the main phytochemical from Cortex Moutan. Its main pharmacological effects are anti-inflammatory and antioxidant, but its cardioprotective effect is unclear. The study investigates the effects and underlying mechanisms of PAE on transverse aortic constriction (TAC)-induced heart fa...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical biology 2022-12, Vol.60 (1), p.562-569 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 569 |
|---|---|
| container_issue | 1 |
| container_start_page | 562 |
| container_title | Pharmaceutical biology |
| container_volume | 60 |
| creator | Chen, Xu Zhang, Zhiyu Zhang, Xiaowei Jia, Zhi Liu, Jun Chen, Xinpei Xu, Aiqing Liang, Xue Li, Guangping |
| description | Paeonol (PAE) is the main phytochemical from Cortex Moutan. Its main pharmacological effects are anti-inflammatory and antioxidant, but its cardioprotective effect is unclear.
The study investigates the effects and underlying mechanisms of PAE on transverse aortic constriction (TAC)-induced heart failure (HF) in mice.
C57BL/6 mice were randomly divided into five groups: sham, TAC, PAE10 (TAC + PAE 10 mg/kg), PAE20 (TAC + PAE 20 mg/kg) and PAE 50 (TAC + PAE 50 mg/kg). Paeonol was intragastrically administered to mice for 4 weeks. Mice were anaesthetized with pentobarbital sodium and underwent cardiac echocardiography using echocardiography system. Serum levels of atrial natriuretic peptide (ANP), tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA). Myocardial apoptosis was detected with terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) staining. Haematoxylin-eosin (H&E) and Masson's staining were used for histopathological evaluation. Western and quantitative real-time PCR (qRT-PCR) were performed to detect levels of apoptosis and fibrosis-related proteins.
Echocardiography showed PAE improved cardiac function (LVEF: TAC, 52.3±6.8%; PAE20, 65.8±3.6%; PAE50, 71.4±2.5%) and H&E staining showed PAE alleviated myocardial injury (TAC: 1170.3 ± 134.6 μm
2
; PAE50: 576.0 ± 53.5 μm
2
). Western and qRT-PCR results showed that PAE down-regulated the levels of ANP, BNP and α-MHC. In addition, TUNEL and western results showed PAE significantly inhibited apoptosis. Masson and western results showed PAE inhibited cardiac hypertrophy. Western results showed the ERK1/2/JNK pathway could be inhibited by PAE.
Paeonol regulates ERK1/2/JNK to improve cardiac function, which provides theoretical support for the extensive clinical treatment of HF. |
| doi_str_mv | 10.1080/13880209.2022.2040543 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2636884458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7683700db9f14cb98518c4c8c258668f</doaj_id><sourcerecordid>2761422167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-c8747bde3ab4aacbbd757726a4640492f9fb9d64ace028bdf838ed2f7825e4603</originalsourceid><addsrcrecordid>eNp9kk1vVCEUhm-MxtbqT9CQuHEzLd9wN8amqdrYRGN0jVw-pkwYqMAdM_9expk21oUbIPCc95zDeYfhJYKnCEp4hoiUEMPxFEOM-0Iho-TRcIwEpQuGEH_cz51Z7KCj4VmtKwghI4Q9HY4Iw3SkTB4PP75ol1OOQLfm0qybq-DG6dKA1yHOxYGQ7GycBdMWtKJT3bhSHdC5tGCAyam2EkwLOYFN0ODy6yd0hkENy6RjDGn5fHjidazuxWE_Gb6_v_x28XFx_fnD1cX59cIwjtvCSEHFZB3RE9XaTJMVTAjMNeUU0hH70U-j5VQbB7GcrJdEOou9kJg5yiE5Ga72ujbrlbotYa3LVmUd1J-LXJZK70qOTgkuiYDQTqNH1EyjZEgaaqTBTHIufdd6u9e6nae1s8al3nl8IPrwJYUbtcwbJUdIxEi7wJuDQMk_Z1ebWodqXIw6uTxXhTnhUtI-gY6-_gdd5bn0z-uU4IhijLjoFNtTpuRai_P3xSCodn5Qd35QOz-ogx963Ku_O7mPujNAB97tgZB8Lmv9K5doVdPbmIvv4zahKvL_HL8Bn7vFKg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2761422167</pqid></control><display><type>article</type><title>Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Xu ; Zhang, Zhiyu ; Zhang, Xiaowei ; Jia, Zhi ; Liu, Jun ; Chen, Xinpei ; Xu, Aiqing ; Liang, Xue ; Li, Guangping</creator><creatorcontrib>Chen, Xu ; Zhang, Zhiyu ; Zhang, Xiaowei ; Jia, Zhi ; Liu, Jun ; Chen, Xinpei ; Xu, Aiqing ; Liang, Xue ; Li, Guangping</creatorcontrib><description>Paeonol (PAE) is the main phytochemical from Cortex Moutan. Its main pharmacological effects are anti-inflammatory and antioxidant, but its cardioprotective effect is unclear.
The study investigates the effects and underlying mechanisms of PAE on transverse aortic constriction (TAC)-induced heart failure (HF) in mice.
C57BL/6 mice were randomly divided into five groups: sham, TAC, PAE10 (TAC + PAE 10 mg/kg), PAE20 (TAC + PAE 20 mg/kg) and PAE 50 (TAC + PAE 50 mg/kg). Paeonol was intragastrically administered to mice for 4 weeks. Mice were anaesthetized with pentobarbital sodium and underwent cardiac echocardiography using echocardiography system. Serum levels of atrial natriuretic peptide (ANP), tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA). Myocardial apoptosis was detected with terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) staining. Haematoxylin-eosin (H&E) and Masson's staining were used for histopathological evaluation. Western and quantitative real-time PCR (qRT-PCR) were performed to detect levels of apoptosis and fibrosis-related proteins.
Echocardiography showed PAE improved cardiac function (LVEF: TAC, 52.3±6.8%; PAE20, 65.8±3.6%; PAE50, 71.4±2.5%) and H&E staining showed PAE alleviated myocardial injury (TAC: 1170.3 ± 134.6 μm
2
; PAE50: 576.0 ± 53.5 μm
2
). Western and qRT-PCR results showed that PAE down-regulated the levels of ANP, BNP and α-MHC. In addition, TUNEL and western results showed PAE significantly inhibited apoptosis. Masson and western results showed PAE inhibited cardiac hypertrophy. Western results showed the ERK1/2/JNK pathway could be inhibited by PAE.
Paeonol regulates ERK1/2/JNK to improve cardiac function, which provides theoretical support for the extensive clinical treatment of HF.</description><identifier>ISSN: 1388-0209</identifier><identifier>EISSN: 1744-5116</identifier><identifier>DOI: 10.1080/13880209.2022.2040543</identifier><identifier>PMID: 35249458</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Acetophenones - pharmacology ; Animals ; Aorta ; Aorta - physiopathology ; Apoptosis ; Apoptosis - drug effects ; Atrial natriuretic peptide ; cardiac fibrosis ; Cardiac function ; Cardiomegaly - prevention & control ; Cardiotonic Agents - pharmacology ; Congestive heart failure ; Constriction, Pathologic - complications ; Disease Models, Animal ; DNA nucleotidylexotransferase ; Echocardiography ; Enzyme-linked immunosorbent assay ; ERK1/2 ; Extracellular signal-regulated kinase ; Fibrosis ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Hypertrophy ; Inflammation ; Interleukin 6 ; Labeling ; Major histocompatibility complex ; Male ; MAP Kinase Signaling System - drug effects ; Mice ; Mice, Inbred C57BL ; Paeonol ; Pentobarbital ; Serum levels ; Signal transduction ; Signal Transduction - drug effects ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Tumors</subject><ispartof>Pharmaceutical biology, 2022-12, Vol.60 (1), p.562-569</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-c8747bde3ab4aacbbd757726a4640492f9fb9d64ace028bdf838ed2f7825e4603</citedby><cites>FETCH-LOGICAL-c562t-c8747bde3ab4aacbbd757726a4640492f9fb9d64ace028bdf838ed2f7825e4603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903794/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903794/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2106,27511,27933,27934,53800,53802,59152,59153</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35249458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Xu</creatorcontrib><creatorcontrib>Zhang, Zhiyu</creatorcontrib><creatorcontrib>Zhang, Xiaowei</creatorcontrib><creatorcontrib>Jia, Zhi</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Chen, Xinpei</creatorcontrib><creatorcontrib>Xu, Aiqing</creatorcontrib><creatorcontrib>Liang, Xue</creatorcontrib><creatorcontrib>Li, Guangping</creatorcontrib><title>Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling</title><title>Pharmaceutical biology</title><addtitle>Pharm Biol</addtitle><description>Paeonol (PAE) is the main phytochemical from Cortex Moutan. Its main pharmacological effects are anti-inflammatory and antioxidant, but its cardioprotective effect is unclear.
The study investigates the effects and underlying mechanisms of PAE on transverse aortic constriction (TAC)-induced heart failure (HF) in mice.
C57BL/6 mice were randomly divided into five groups: sham, TAC, PAE10 (TAC + PAE 10 mg/kg), PAE20 (TAC + PAE 20 mg/kg) and PAE 50 (TAC + PAE 50 mg/kg). Paeonol was intragastrically administered to mice for 4 weeks. Mice were anaesthetized with pentobarbital sodium and underwent cardiac echocardiography using echocardiography system. Serum levels of atrial natriuretic peptide (ANP), tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA). Myocardial apoptosis was detected with terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) staining. Haematoxylin-eosin (H&E) and Masson's staining were used for histopathological evaluation. Western and quantitative real-time PCR (qRT-PCR) were performed to detect levels of apoptosis and fibrosis-related proteins.
Echocardiography showed PAE improved cardiac function (LVEF: TAC, 52.3±6.8%; PAE20, 65.8±3.6%; PAE50, 71.4±2.5%) and H&E staining showed PAE alleviated myocardial injury (TAC: 1170.3 ± 134.6 μm
2
; PAE50: 576.0 ± 53.5 μm
2
). Western and qRT-PCR results showed that PAE down-regulated the levels of ANP, BNP and α-MHC. In addition, TUNEL and western results showed PAE significantly inhibited apoptosis. Masson and western results showed PAE inhibited cardiac hypertrophy. Western results showed the ERK1/2/JNK pathway could be inhibited by PAE.
Paeonol regulates ERK1/2/JNK to improve cardiac function, which provides theoretical support for the extensive clinical treatment of HF.</description><subject>Acetophenones - pharmacology</subject><subject>Animals</subject><subject>Aorta</subject><subject>Aorta - physiopathology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Atrial natriuretic peptide</subject><subject>cardiac fibrosis</subject><subject>Cardiac function</subject><subject>Cardiomegaly - prevention & control</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Congestive heart failure</subject><subject>Constriction, Pathologic - complications</subject><subject>Disease Models, Animal</subject><subject>DNA nucleotidylexotransferase</subject><subject>Echocardiography</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>ERK1/2</subject><subject>Extracellular signal-regulated kinase</subject><subject>Fibrosis</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Hypertrophy</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Labeling</subject><subject>Major histocompatibility complex</subject><subject>Male</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Paeonol</subject><subject>Pentobarbital</subject><subject>Serum levels</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Tumors</subject><issn>1388-0209</issn><issn>1744-5116</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1vVCEUhm-MxtbqT9CQuHEzLd9wN8amqdrYRGN0jVw-pkwYqMAdM_9expk21oUbIPCc95zDeYfhJYKnCEp4hoiUEMPxFEOM-0Iho-TRcIwEpQuGEH_cz51Z7KCj4VmtKwghI4Q9HY4Iw3SkTB4PP75ol1OOQLfm0qybq-DG6dKA1yHOxYGQ7GycBdMWtKJT3bhSHdC5tGCAyam2EkwLOYFN0ODy6yd0hkENy6RjDGn5fHjidazuxWE_Gb6_v_x28XFx_fnD1cX59cIwjtvCSEHFZB3RE9XaTJMVTAjMNeUU0hH70U-j5VQbB7GcrJdEOou9kJg5yiE5Ga72ujbrlbotYa3LVmUd1J-LXJZK70qOTgkuiYDQTqNH1EyjZEgaaqTBTHIufdd6u9e6nae1s8al3nl8IPrwJYUbtcwbJUdIxEi7wJuDQMk_Z1ebWodqXIw6uTxXhTnhUtI-gY6-_gdd5bn0z-uU4IhijLjoFNtTpuRai_P3xSCodn5Qd35QOz-ogx963Ku_O7mPujNAB97tgZB8Lmv9K5doVdPbmIvv4zahKvL_HL8Bn7vFKg</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Chen, Xu</creator><creator>Zhang, Zhiyu</creator><creator>Zhang, Xiaowei</creator><creator>Jia, Zhi</creator><creator>Liu, Jun</creator><creator>Chen, Xinpei</creator><creator>Xu, Aiqing</creator><creator>Liang, Xue</creator><creator>Li, Guangping</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202212</creationdate><title>Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling</title><author>Chen, Xu ; Zhang, Zhiyu ; Zhang, Xiaowei ; Jia, Zhi ; Liu, Jun ; Chen, Xinpei ; Xu, Aiqing ; Liang, Xue ; Li, Guangping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-c8747bde3ab4aacbbd757726a4640492f9fb9d64ace028bdf838ed2f7825e4603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acetophenones - pharmacology</topic><topic>Animals</topic><topic>Aorta</topic><topic>Aorta - physiopathology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Atrial natriuretic peptide</topic><topic>cardiac fibrosis</topic><topic>Cardiac function</topic><topic>Cardiomegaly - prevention & control</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Congestive heart failure</topic><topic>Constriction, Pathologic - complications</topic><topic>Disease Models, Animal</topic><topic>DNA nucleotidylexotransferase</topic><topic>Echocardiography</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>ERK1/2</topic><topic>Extracellular signal-regulated kinase</topic><topic>Fibrosis</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Hypertrophy</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Labeling</topic><topic>Major histocompatibility complex</topic><topic>Male</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Paeonol</topic><topic>Pentobarbital</topic><topic>Serum levels</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Xu</creatorcontrib><creatorcontrib>Zhang, Zhiyu</creatorcontrib><creatorcontrib>Zhang, Xiaowei</creatorcontrib><creatorcontrib>Jia, Zhi</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Chen, Xinpei</creatorcontrib><creatorcontrib>Xu, Aiqing</creatorcontrib><creatorcontrib>Liang, Xue</creatorcontrib><creatorcontrib>Li, Guangping</creatorcontrib><collection>Access via Taylor & Francis (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Xu</au><au>Zhang, Zhiyu</au><au>Zhang, Xiaowei</au><au>Jia, Zhi</au><au>Liu, Jun</au><au>Chen, Xinpei</au><au>Xu, Aiqing</au><au>Liang, Xue</au><au>Li, Guangping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling</atitle><jtitle>Pharmaceutical biology</jtitle><addtitle>Pharm Biol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>60</volume><issue>1</issue><spage>562</spage><epage>569</epage><pages>562-569</pages><issn>1388-0209</issn><eissn>1744-5116</eissn><abstract>Paeonol (PAE) is the main phytochemical from Cortex Moutan. Its main pharmacological effects are anti-inflammatory and antioxidant, but its cardioprotective effect is unclear.
The study investigates the effects and underlying mechanisms of PAE on transverse aortic constriction (TAC)-induced heart failure (HF) in mice.
C57BL/6 mice were randomly divided into five groups: sham, TAC, PAE10 (TAC + PAE 10 mg/kg), PAE20 (TAC + PAE 20 mg/kg) and PAE 50 (TAC + PAE 50 mg/kg). Paeonol was intragastrically administered to mice for 4 weeks. Mice were anaesthetized with pentobarbital sodium and underwent cardiac echocardiography using echocardiography system. Serum levels of atrial natriuretic peptide (ANP), tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA). Myocardial apoptosis was detected with terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) staining. Haematoxylin-eosin (H&E) and Masson's staining were used for histopathological evaluation. Western and quantitative real-time PCR (qRT-PCR) were performed to detect levels of apoptosis and fibrosis-related proteins.
Echocardiography showed PAE improved cardiac function (LVEF: TAC, 52.3±6.8%; PAE20, 65.8±3.6%; PAE50, 71.4±2.5%) and H&E staining showed PAE alleviated myocardial injury (TAC: 1170.3 ± 134.6 μm
2
; PAE50: 576.0 ± 53.5 μm
2
). Western and qRT-PCR results showed that PAE down-regulated the levels of ANP, BNP and α-MHC. In addition, TUNEL and western results showed PAE significantly inhibited apoptosis. Masson and western results showed PAE inhibited cardiac hypertrophy. Western results showed the ERK1/2/JNK pathway could be inhibited by PAE.
Paeonol regulates ERK1/2/JNK to improve cardiac function, which provides theoretical support for the extensive clinical treatment of HF.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>35249458</pmid><doi>10.1080/13880209.2022.2040543</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1388-0209 |
| ispartof | Pharmaceutical biology, 2022-12, Vol.60 (1), p.562-569 |
| issn | 1388-0209 1744-5116 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2636884458 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Taylor & Francis (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Acetophenones - pharmacology Animals Aorta Aorta - physiopathology Apoptosis Apoptosis - drug effects Atrial natriuretic peptide cardiac fibrosis Cardiac function Cardiomegaly - prevention & control Cardiotonic Agents - pharmacology Congestive heart failure Constriction, Pathologic - complications Disease Models, Animal DNA nucleotidylexotransferase Echocardiography Enzyme-linked immunosorbent assay ERK1/2 Extracellular signal-regulated kinase Fibrosis Heart failure Heart Failure - drug therapy Heart Failure - physiopathology Hypertrophy Inflammation Interleukin 6 Labeling Major histocompatibility complex Male MAP Kinase Signaling System - drug effects Mice Mice, Inbred C57BL Paeonol Pentobarbital Serum levels Signal transduction Signal Transduction - drug effects Tumor necrosis factor-TNF Tumor necrosis factor-α Tumors |
| title | Paeonol attenuates heart failure induced by transverse aortic constriction via ERK1/2 signalling |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T07%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paeonol%20attenuates%20heart%20failure%20induced%20by%20transverse%20aortic%20constriction%20via%20ERK1/2%20signalling&rft.jtitle=Pharmaceutical%20biology&rft.au=Chen,%20Xu&rft.date=2022-12&rft.volume=60&rft.issue=1&rft.spage=562&rft.epage=569&rft.pages=562-569&rft.issn=1388-0209&rft.eissn=1744-5116&rft_id=info:doi/10.1080/13880209.2022.2040543&rft_dat=%3Cproquest_cross%3E2761422167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2761422167&rft_id=info:pmid/35249458&rft_doaj_id=oai_doaj_org_article_7683700db9f14cb98518c4c8c258668f&rfr_iscdi=true |